Multiple-dose pharmacokinetics of peginterferon alfa-2b in patients with renal insufficiency

British Journal of Clinical Pharmacology

Volumn 64, Issue 6, 2007, Pages 726-732

  Gupta, Samir K ^a   Swan, Suzanne K ^b   Marbury, Thomas ^c   Smith, William ^d   Schwartz, Sherwyn ^e   Kolz, Karen ^f   Cutler, David L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b HENNEPIN COUNTY MEDICAL CENTER   (United States)

^c ORLANDO CLINICAL RESEARCH CENTER   (United States)

^d New Orleans Center for Clinical Research   (United States)

^e Diabetes and Glandular Disease Clinic   (United States)

^f Pharmaceutical Sciences   (United States)

Author keywords

Interferon alfa 2b; Pegylation; Pharmacokinetics; Renal insufficiency

Indexed keywords

PEGINTERFERON ALPHA2B;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; HEADACHE; HUMAN; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; INJECTION SITE INFLAMMATION; KIDNEY FAILURE; KIDNEY FUNCTION; LEUKOPENIA; MALE; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RIGOR; THROMBOCYTOPENIA; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTERFERON ALFA-2B; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; RENAL INSUFFICIENCY;

EID: 36849004507     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.02950.x     Document Type: Article

References (18)

1. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002 36 : 3 10.
2. Bocci V, Pacini A, Muscettola M, Pessina GP, Paulesu L, Bandinelli L. The kidney is the main site of interferon catabolism. J Interferon Res 1982 2 : 309 14.
3. Zeuzem S, Welsch C, Herrmann E. Pharmacokinetics of peginterferons. Semin Liver Dis 2003 23 : 23 8.
4. Gupta SK, Pittenger AL, Swan SK, Marbury TC, Tobillo E, Batra V, Sack M, Glue P, Jacobs S, Affrime M. Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction. J Clin Pharmacol 2002 42 : 1109 15.
5. Glue P, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S, Clement RP. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology 2000 32 : 647 53.
6. Czock D, Rasche FM. Dose adjustment of ciprofloxacin in renal failure: reduce the dose or prolong the administration interval? Eur J Med Res 2005 10 : 145 8.
7. Fischer KG. Hirudin in renal insufficiency. Semin Thromb Hemost 2002 28 : 467 82.
8. Anderson GD, Odegard PS. Pharmacokinetics of estrogen and progesterone in chronic kidney disease. Adv Chronic Kidney Dis 2004 11 : 357 60.
9. Carlson K, Hjorth M, Knudsen LM, Nordic Myeloma Study Group. Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure - a retrospective analysis and recommendations for dose adjustment. Br J Haematol 2005 128 : 631 5.
10. Vogel W. Peginterferon-alpha 2a (40 kDa)/ribavirin combination for the treatment of chronic hepatitis C infection. Exp Rev Anti-Infective Ther 2003 1 : 423 31.
11. Bruchfeld A, Lindahl K, Stahle L, Soderberg M, Schvarcz R. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant 2003 18 : 1573 80.
12. Poordad FF, Fabrizi F, Martin P. Hepatitis C infection associated with renal disease and chronic renal failure. Semin Liver Dis 2004 24 : 69 77.
13. Gupta SK, Glue P, Jacobs S, Belle D, Affrime M. Single-dose pharmacokinetics and tolerability of pegylated interferon-alpha2b in young and elderly healthy subjects. Br J Clin Pharmacol 2003 56 : 131 4.
14. Bex A, Mallo H, Kerst M, Haanen J, Horenblas S, de Gast GC. A phase-II study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumor. Cancer Immunol Immunother 2005 54 : 713 9.
15. Cariti G, Quaglia S, Meoli I, Veronese L, Audaqnotto S, DeBlasi T, Mancardi E, Raiteri R, DiPerri G. Is a 3-month course of treatment with Peg-interferon effective in acute HCV hepatitis? J Biol Regul Homeost Agents 2003 17 : 188 90.
16. Bukowski R, Ernstoff MS, Gore ME, Nemunaitis JJ, Amato R, Gupta SK, Tandler CL. Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study. J Clin Oncol 2002 20 : 3841 9.
17. Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf 2001 24 : 19 38.
18. Feingold KR, Grunfeld C. Role of cytokines in inducing hyperlipidemia. Diabetes 1992 41 : 97 101.